KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Liabilities and Shareholders Equity (2019 - 2025)

GoodRx Holdings' Liabilities and Shareholders Equity history spans 6 years, with the latest figure at $1.4 billion for Q4 2024.

  • For Q4 2024, Liabilities and Shareholders Equity fell 12.63% year-over-year to $1.4 billion; the TTM value through Sep 2025 reached $1.4 billion, down 76.37%, while the annual FY2024 figure was $1.4 billion, 12.63% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2024 was $1.4 billion at GoodRx Holdings, up from $1.4 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.7 billion in Q3 2023 and bottomed at $1.4 billion in Q3 2024.
  • The 5-year median for Liabilities and Shareholders Equity is $1.6 billion (2021), against an average of $1.6 billion.
  • The largest annual shift saw Liabilities and Shareholders Equity skyrocketed 280.07% in 2020 before it dropped 20.68% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.5 billion in 2020, then grew by 9.35% to $1.6 billion in 2021, then fell by 0.19% to $1.6 billion in 2022, then decreased by 0.99% to $1.6 billion in 2023, then decreased by 12.63% to $1.4 billion in 2024.
  • Per Business Quant, the three most recent readings for GDRX's Liabilities and Shareholders Equity are $1.4 billion (Q4 2024), $1.4 billion (Q3 2024), and $1.5 billion (Q2 2024).